GlaxoSmithKline's cancer vaccine misses primary endpoint

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

GlaxoSmithKline's (GSK) experimental cancer vaccine MAGE-A3 misses one of its primary endpoints in a Phase 3 melanoma trial.

The antigen-specific cancer immunotherapeutic did not significantly extend disease-free survival compared to placebo.

The company says it remains "committed to identifying a patient sub-population who may benefit from this investigational treatment."

Data regarding a second endpoint and results from a Phase 3 trial of MAGE-A3 in non-small cell lung cancer are due in 2015 and H1 2014 respectively.